



CSU
College of Law Library

2004

Sources: Pharmaceutical Promotion and the Medical Profession: Appendix A

Joseph Rohan Lex Jr.
Temple University School of Medicine

Follow this and additional works at: <https://engagedscholarship.csuohio.edu/jlh>



Part of the [Food and Drug Law Commons](#), and the [Health Law and Policy Commons](#)

[How does access to this work benefit you? Let us know!](#)

Recommended Citation

Joseph Rohan Lex, Jr., Sources: Pharmaceutical Promotion and the Medical Profession, Appendix A, 2005 Speaker Series, 18 J.L. & Health 337 (2003-2004)

This Article is brought to you for free and open access by the Journals at EngagedScholarship@CSU. It has been accepted for inclusion in Journal of Law and Health by an authorized editor of EngagedScholarship@CSU. For more information, please contact library.es@csuohio.edu.

APPENDIX A

SOURCES: PHARMACEUTICAL PROMOTION AND THE MEDICAL PROFESSION

Attitudes and Practice

- Bellin M, McCarthy S, Drevlow L, Pierach C. Medical Students' Exposure to Pharmaceutical Industry Marketing: A Survey at One U.S. Medical School. *Acad Med.* 2004 Nov;79(11):1041-5.
- Brett AS, Burr W, Moloo J. Are gifts from pharmaceutical companies ethically problematic? A survey of physicians. *Arch Intern Med.* 2003;2213-8.
- Brotzman GL, Mark DH. Policies regulating the activities of pharmaceutical representatives in residency programs. *J Fam Pract.* 1992 Jan;34(1):54-7.
- Gibbons RV, Landry FJ, Blouch DL, et al. A comparison of physicians' and patients' attitudes toward pharmaceutical industry gifts. *JGIM.* 1998; 13:151-154.
- Halperin EC, Hutchison P, Barrier RC Jr. A population-based study of the prevalence and influence of gifts to radiation oncologists. *Int J Radiat Oncol Biol Phys.* 2004 Aug 1;59(5):1477-83.
- Hodges B. Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks. *CMAJ* 1995 Sep 1;153(5):553-9.
- Keim SM, Mays MZ, Grant D. Interactions between emergency medicine programs and the pharmaceutical industry. *Acad Emerg Med.* 2004 Jan;11(1):19-26.
- Lurie N, Rich EC, Simpson DE, et al. Pharmaceutical representatives in academic medical centers: Interaction with faculty and housestaff. *JGIM* 1990;5:240-243.
- Mainous III AG, Hueston WJ, Rich EC. Patient perceptions of physician acceptance of gifts from the pharmaceutical industry. *Arch Fam Med.* 4; 1995: 335-9.
- McKinney WP, Schiedermayer DL, Lurie N, et al. Attitudes of internal medicine faculty and residents toward professional interaction with pharmaceutical sales representatives. *JAMA.* 1990 Oct 3;264(13):1693-7.
- Sandberg WS, Carlos R, Sandberg EH, Roizen MF. The effect of educational gifts from pharmaceutical firms on medical students' recall of company names or products. *Acad Med.* 1997 Oct;72(10):916-8.

- Steinman MA, Shlipak MG, McPhee SJ. Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. *Am J Med* 2001 May;110(7):551-7.
- Vinson DC, McCandless B, Hosokawa MC. Medical students' attitudes toward pharmaceutical marketing: possibilities for change. *Fam Med*. 1993 Jan;25(1):31-3.
- Watkins RS, Kimberly J Jr. What residents don't know about physician-pharmaceutical industry interactions. *Acad Med*. 2004 May;79(5):432-7.

Influence on Behavior, Belief, and Attitudes

- Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. *Am J Med*. 1982;73:4-8.
- Caudill, TS, Johnson, MS, Rich EC, McKinney, WP. Physicians, pharmaceutical sales representatives, and the cost of prescribing. *Arch of Fam Med*. 1996;5:201-206.
- Chew LD, O'Young TS, Hazlet TK, Bradley KA, Maynard C, Lessler DS. A physician survey of the effect of drug sample availability on physicians' behavior. *J Gen Intern Med*. 2000 Jul;15(7):478-83.
- Chren MM, Landefeld CS. Physicians' behavior and their interaction with drug companies. *JAMA*. 1994;271:684-689.
- Orłowski JP and Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. *Chest*. 1992; 102:270-273.
- Peay MY, Peay ER. The role of commercial sources in the adoption of a new drug. *Soc Sci Med* 1988;26:1183-9.

Bias in Promotional Materials

- Cooper RJ, Schriger DL, Wallace RC, Mikulich VJ, Wilkes MS. The quantity and quality of scientific graphs in pharmaceutical advertisements. *J Gen Intern Med*. 2003 Apr;18(4):294-7.
- Shaughnessy AF, Slawson DC, Bennett JH. Separating the wheat from the chaff: identifying fallacies in pharmaceutical promotion. *J of Gen Int Med*. 1994; 10:563-8.
- Stryer, D and Bero, LA. Characteristics of materials distributed by drug companies. An evaluation of appropriateness. *J Gen Int Med*. 1996;11:575-583.
- Villanueva P, Peiro S, Librero J, Pereiro I. Accuracy of pharmaceutical advertisements in medical journals. *Lancet*. 2003 Jan 4;361(9351):27-32.
- Wilkes MS, Doblin BH, Shapiro MF. Pharmaceutical advertisements in leading medical journals: experts' assessments. *Ann Intern Med* 1992;116:912-9.

- Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical sales representatives. *JAMA*. 1995;273:1296-1298. Comments in *JAMA*. 1995;274:1267-1268.

Educational Interventions

- Agrawal S, Saluja I, Kaczorowski J. A prospective before-and-after trial of an educational intervention about pharmaceutical marketing. *Acad Med*. 2004 Nov;79(11):1046-50.
- Hopper JA, Speece MW, Musial JL. Effects of an educational intervention on residents' knowledge and attitudes toward interactions with pharmaceutical representatives. *J Gen Intern Med*. 1997 Oct;12(10):639-42.
- McCormick BB, Tomlinson G, Brill-Edwards P, Detsky AS. Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior. *JAMA*. 2001 Oct 24-31;286(16):1994-9.

Industry Funding and Research

- Bero LA, Galbraith A, Rennie D. The publication of sponsored symposiums in medical journals. *N Engl J Med* 1992;327:1135-40.
- Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. *Ann Intern Med* 1996;124:485-9.
- Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. *JAMA*. 2002 Feb 6;287(5):612-7.
- Davidson RA. Source of funding and outcome of clinical trials. *J Gen Intern Med* 1986;1:155-8.
- Friedberg M, et al. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. *JAMA* 1999;282:1453-7.
- Krinsky S, Rothenberg LS, Stott P, Kyle G. Scientific journals and their authors' financial interests: a pilot study. *Psychother Psychosom*. 1998 Jul-Oct;67(4-5):194-201.
- Rochon PA, Gurwitz JH, Cheung CM, Hayes JA, Chalmers TC. Evaluating the quality of articles published in journal supplements compared with the quality of those published in the parent journal. *JAMA*. 1994 Jul 13;272(2):108-13.
- Rochon PA, Bero LA, Bay AM, Gold JL, Dergal JM, Binns MA, Streiner DL, Gurwitz JH. Comparison of review articles published in peer-reviewed and throwaway journals. *JAMA*. 2002 Jun 5;287(21):2853-6.
- Rochon PA, Gurwitz JH, Simms RW, Fortin PR, Felson DT, Minaker KL, Chalmers TC. A study of manufacturer-supported trials of

nonsteroidal anti-inflammatory drugs in the treatment of arthritis. *Arch Intern Med.* 1994 Jan 24;154(2):157-63.

- Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonists. *N Engl J Med.* 1998 Jan 8;338(2):101-6.

Pharmaceutical Samples

- Backer EL, Lebsack JA, Van Tonder RJ, Crabtree BF. The value of pharmaceutical representative visits and medication samples in community-based family practices. *J Fam Pract.* 2000 Sep;49(9):811-6.
- Christie JD, Rosen IM, Bellini LM, Inglesby TV, Lindsay J, Alper A, Asch DA. Prescription drug use and self-prescription among resident physicians. *JAMA.* 1998 Oct 14;280(14):1253-5.
- Shaughnessy AF, Bucci KK. Drug samples and family practice residents. *Ann Pharmacother.* 1997 Nov;31(11):1296-300.
- Tong KL, Lien CY. Do pharmaceutical representatives misuse their drug samples? *Can Fam Physician.* 1995 Aug;41:1363-6.
- Westfall JM, McCabe H, Nicholas RA. Personal use of drug samples by physicians and office staff. *JAMA.* 1997;278:141-143. Comments in *JAMA.* 1998;279:1698-99.

Systematic Reviews

- Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? *JAMA.* 2003 Aug 20;290(7):921-8.
- Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. *JAMA.* 2003;289:454-65.
- Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. *BMJ.* 2003 May 31;326(7400):1167-70.
- Lexchin J. What information do physicians receive from pharmaceutical representatives? *Can Fam Phys* 1997;43:941-945.
- Lexchin J. Interactions between physicians and the pharmaceutical industry: what does the literature say? *CMAJ.* 1993; 149:1401-7.
- Wazana A, Primeau F. Ethical considerations in the relationship between physicians and the pharmaceutical industry. *Psychiatr Clin North Am.* 2002 Sep;25(3):647-63, viii.
- Wazana A. Gifts to physicians from the pharmaceutical industry. *JAMA.* 2000 May 24;283(20):2655-8.
- Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? *JAMA.* 2000 Jan 19;283(3):373-80.

Commentaries, Essays, and Editorials

- Abbasi K, Smith R. No more free lunches. *BMJ*. 2003 May 31;326(7400):1155-6.
- Angell M. The Pharmaceutical Industry: To Whom is it Accountable? *NEJM*. 2000;342:1902-1904.
- Berger JT. Pharmaceutical industry influences on physician prescribing: gifts, quasi-gifts, and patient-directed gifts. *Am J Bioeth*. 2003 Summer;3(3):56-7.
- Chren MM, Landefeld S, Murray TH. Doctors, drug companies, and gifts. *JAMA* 1989;262:3448-51.
- Dana J, Loewenstein GA. Social science perspective on gifts to physicians from industry. *JAMA*. 2003;290:252-255.
- Griffith D. Reasons for not seeing drug reps. *BMJ*. 1999; 319: 69-70.
- Kassirer J. Financial indigestion. *JAMA*. 2000;284:2156-7.
- Katz D, Caplan AL, Merz JF. All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift giving. *Am J Bioeth*. 2003 Summer;3(3):39-46.
- Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: Entanglement. *BMJ*. 2003 May 31;326(7400):1189-92.
- Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 2: Disentanglement. *BMJ*. 2003 May 31;326(7400):1193-6.
- Shaughnessy AF, Slawson DC. Pharmaceutical representatives (editorial). *BMJ*. 1996;312:1494.
- Waud DR. Pharmaceutical promotions--a free lunch? *N Engl J Med*. 1992;327:351-3.
- Wazana A, Primeau F. Ethical Considerations in the relationship between physicians and the pharmaceutical industry. *Psychiatr Clin North Am*. 2002 Sep;25(3):647-63.

Position Papers and Guidelines

- American College of Physicians-American Society of Internal Medicine. Position Paper: Physician-Industry Relations. Part 1: Individual Physicians. *Ann Intern Med*. 2002;136:396-402.
- American College of Physicians-American Society of Internal Medicine. Position Paper: Physician-Industry Relations. Part 2: Organizational Issues. *Ann Intern Med*. 2002;136:403-406.
- Canadian Medical Association Policy Summary: Physicians and the pharmaceutical industry. *CMAJ*, Feb 1, 1992.
- Council on Ethical and Judicial Affairs, American Medical Association. Gifts to physicians from industry. *JAMA*, 1991; 261: 501.

- Council on Ethical and Judicial Affairs, American Medical Association. Guidelines on gifts to physicians from industry: an update. *Food and Drug Law Journal*, 1992; 47:445-458.
- Royal College of Physicians: The Relationship between physicians and the pharmaceutical industry. *Journal of the Royal College of Physicians of London*, 1986. 20(4):235-42.

Books

- John Abramson: Overdosed America : The Broken Promise of American Medicine
- Marcia Angell: The Truth About Drug Companies: How They Deceive Us and What to Do About It
- Jerry Avorn: Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs
- Donald L. Barlett: Critical Condition: How Health Care in America Became Big Business--and Bad Medicine
- Merrill Goozner: The \$800 Million Pill: The Truth Behind the Cost of New Drugs
- Jerome Kassirer: On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health

Websites

<http://www.nofreelunch.org> - take the pledge!!
<http://www.healthskepticism.org>
<http://www.drugpromo.info/>
<http://www.medletter.com>
<http://www.ti.ubc.ca/index.html> - Therapeutics Initiative
<http://www.dtb.org.uk/dtb/index.html> - Drug and Therapies Bulletin